4-苄氧基-2(1H)-吡啶酮 | 53937-02-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-苄氧基-2(1H)-吡啶酮
• 中文别名: 4-苄氧基吡啶-2-酮；4-苯甲氧基-2-羟基吡啶
• 英文名称: 4-(benzyloxy)pyridin-2(1H)-one
• 英文别名: 4-benzyloxy-1H-pyridin-2-one；4-benzyloxy-2(1H)-pyridone；4-phenylmethoxy-1H-pyridin-2-one
• CAS: 53937-02-3
• 化学式: C₁₂H₁₁NO₂
• mdl: MFCD00191783
• 分子量: 201.225
• InChiKey: DOVNUEPFPBWTSV-UHFFFAOYSA-N

物化性质

• 熔点：
  201-203 °C (lit.)
• 沸点：
  464.3±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)
• 溶解度：
  >30.2 [ug/mL]
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  将物品存放在紧密的储存器中，并储存在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Benzyloxy-2(1h)-pyridone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzyloxy-2(1h)-pyridone
CAS number: 53937-02-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H11NO2
Molecular weight: 201.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苄氧基-2(1H)-吡啶酮 在 三氯氧磷 、 sodium hydroxide 、 sodium carbonate 作用下， 以 水 为溶剂， 以47.1%的产率得到2-氯-4-苄氧基吡啶
  参考文献：
  名称：

  WO2007/89512

  摘要：

  公开号：
• 作为产物：
  描述：

  4-苄氧基吡啶 N-氧化物 在 sodium carbonate 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 三氟乙酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 25.0~50.0 ℃ 、101.33 kPa 条件下， 反应 41.0h， 生成 4-苄氧基-2(1H)-吡啶酮
  参考文献：
  名称：

  (环丙基甲氧基)嗪醚制备吖嗪酮

  摘要：

  介绍了用于合成 azinones 的通用且方便的程序。环丙基甲醇很容易被引入到各种吖嗪中，它既可以作为羟基的保护基，也可以作为羟基的替代物。酸性脱保护后，在温和的反应条件下，相应的吖酮形成并以优异的收率分离。包括超过 20 个示例以及对反应优化、范围和机制的讨论。

  DOI：

  10.1021/acs.joc.3c00145
• 作为试剂：
  描述：

  N-butylpicolinamide 、 二(2-甲氧基苯基)二硫醚 在 4-苄氧基-2(1H)-吡啶酮 、 palladium diacetate 作用下， 以30 %的产率得到
  参考文献：
  名称：

  长链吡啶甲酰胺 δ 和 γ 位之间配体控制的正交选择性

  摘要：

  脂肪族 C(sp 3 )–H 键由于其惰性和化学不可区分性，本质上难以激活。这一挑战主要是通过指导小组的方法来克服的；然而，远端脂肪族位置的区域选择性主要依赖于底物，底物偏向是远端 C(sp 3 )–H 激活的先决条件，这是索普-英戈尔德效应的直接结果。将方法扩展到直链脂肪族底物，其中所有可用位置都与功能化兼容，一直是一个长期存在的问题。为此，我们尝试以区域选择性方式开发长链吡啶甲酰胺远端δ和γ位置之间的配体正交选择性。这些烷基胺在吡啶甲酸导向基团的帮助下，只需改变配体即可在其γ和δ位置之间正交官能化，而所有其他反应参数保持不变，这表明配体在控制之间的选择性方面具有巨大的重要性。这种惰性 C(sp 3 )–H 键的上述位置。已经进行了实验和 DFT 研究来概括配体的性质，该配体将成功地促进这些位置之间的正交选择性，富电子吡啶酮配体有利于选择性远端 δ 官能化，而缺电子吡啶酮配体则有利地调整选择性向γ位置。这种从

  DOI：

  10.1021/acscatal.4c03126

文献信息

• Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships
  作者：Paul S. Charifson、Anne-Laure Grillot、Trudy H. Grossman、Jonathan D. Parsons、Michael Badia、Steve Bellon、David D. Deininger、Joseph E. Drumm、Christian H. Gross、Arnaud LeTiran、Yusheng Liao、Nagraj Mani、David P. Nicolau、Emanuele Perola、Steven Ronkin、Dean Shannon、Lora L. Swenson、Qing Tang、Pamela R. Tessier、Ski-Kai Tian、Martin Trudeau、Tiansheng Wang、Yunyi Wei、Hong Zhang、Dean Stamos

  DOI：10.1021/jm800318d

  日期：2008.9.11

  hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.

  为了克服影响所有目前使用的抗生素种类的细菌耐药性问题，发现具有新颖作用机制的新型抗菌剂是必要的。细菌DNA促旋酶和拓扑异构酶IV是氟喹诺酮类抗生素的特征明确的临床验证靶标，它们通过抑制催化亚基发挥其抗菌活性。通过与它们的ATP位点相互作用来抑制这些靶标在临床上不太成功。提出了一种新型的低分子量，与ATP位点结合的回旋酶和拓扑异构酶IV合成抑制剂的发现和表征。苯并咪唑脲是两种酶的双重靶向抑制剂，并且对引起医院和社区获得性感染的各种相关病原体具有有效的抗菌活性。描述了通过使用结构指导的设计，建模和结构-活性关系来发现和优化这种新型抗菌剂。提供了在两种啮齿动物感染模型中通过口服和静脉内给药的酶抑制，抗菌活性和体内功效的数据。
• Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones
  申请人：Armour R. Duncan

  公开号：US20080085884A1

  公开（公告）日：2008-04-10

  The present invention provides for MCHR1 antagonist compounds of formula (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein the substituents are as defined herein, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are useful in treating diseases or conditions wherein antagonism of the MCHR1 receptor is beneficial.

  本发明提供了式（I）的MCHR1拮抗剂化合物及其药用盐、溶剂合物和前药，其中取代基如本文所定义，并且其药用盐、溶剂合物和前药，可用于治疗对MCHR1受体拮抗有益的疾病或症状。
• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• MODIFIED COMPOUND OF ANDROGRAPHOLIDE
  申请人：Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

  公开号：US20180346438A1

  公开（公告）日：2018-12-06

  The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

  本公开披露了穿心莲内酯的修改化合物，特别是公开了公式(I)和(II)所示的化合物或其药用可接受的盐。
• [EN] 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] 1-(DIHYDRONAPHTALÉNYL)PYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MÉLANINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013149362A1

  公开（公告）日：2013-10-10

  Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.

  提供的是1-(二氢萘基)吡啶酮，它们是黑素浓集激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备过程，以及它们在治疗肥胖和糖尿病方面的用途。